Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives

Cytosolic PIM kinases are the members of serine/ threonine family play a crucial role in the cancer progression and development. Overexpression of PIM kinases is observed in various types of cancers including prostate, hematological, pancreatic, breast carcinoma and likewise. PIM kinases have now been considered as limelight target for the discovery of new molecules as novel anticancer agents as no drug is in the market targeting PIM kinases. In the last two decades, numerous PIM kinase inhibitors have been developed and few of them were in clinical trial phases but could not pass the pipeline of the clinical trials. The present comprehensive review intends to cover biological and the structural aspects of PIM kinases and also medicinal chemistry of PIM inhibitors developed in recent years.

Automated summary

Cytosolic PIM kinases play a crucial role in cancer progression, but there are currently no drugs targeting these kinases on the market. Many PIM kinase inhibitors have been developed in recent years, but have not passed clinical trials.